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ﬂammation and loss of phagocytic activity is considered
to play a prominent role in the pathogenesis of Alzheimer’s
disease (AD). CHF5074 (CSP-1103) has been shown to
improve cognition and reduce brain inﬂammation in patients
with mild cognitive impairment (MCI). CHF5074 was also
found to reverse impairments in recognition memory and
improve hippocampal long-term potentiation when adminis-
tered to plaque-free Tg2576 mice (5-month-old) for 4 weeks.
Though, no investigation has focused on the consequence
of CHF5074 treatment on microglia polarization yet. In this
study we evaluated the eﬀect of CHF5074 administration
(375 ppm in the diet) to 5-month-old Tg2576 mice on the
expression of pro-inﬂammatory (M1) genes, Interleukin 1
beta (IL-1b), Tumor Necrosis Factor alpha (TNFa) and induc-
ible Nitric Oxide Synthase (iNOS), and anti-inﬂammatory/
phagocytic (M2) markers Mannose Receptor type C 1
(MRC1/CD206), Triggering Receptor Expressed on Myeloidhttp://dx.doi.org/10.1016/j.neuroscience.2014.10.029
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1cells 2 (TREM2) and Chitinase 3-like 3 (Ym1). No changes
of pro-inﬂammatory gene transcription but a reduced
expression of MRC1/CD206, TREM2 and Ym1 were detected
in the hippocampus of young Tg2576 mice receiving normal
diet, when compared to wild-type littermates. CHF5074 did
not aﬀect the pro-inﬂammatory transcription but signiﬁ-
cantly increased the expression of MRC1/CD206 and Ym1.
CHF5074 eﬀects appeared to be hippocampus-speciﬁc, as
the M2 transcripts were only slightly modiﬁed in the cerebral
cortex. In primary cultures of mouse astrocyte-microglia,
CHF5074 totally suppressed the expression of TNF-a, IL-1b
and iNOS induced by 10 lM b-amyloid1–42 (Ab42). Moreover,
CHF5074 signiﬁcantly increased the expression of anti-
inﬂammatory/phagocytic markers MRC1/CD206 and TREM2,
reduced by the Ab42 application alone. The eﬀect of CHF5074
was not reproduced by ibuprofen (3 lM or 500 lM) or
R-ﬂurbiprofen (3 lM or 100 lM), as both compounds limited
the pro-inﬂammatory gene expression but did not modify
the anti-inﬂammatory/phagocytic transcription. These data
show that CHF5074 speciﬁcally drives the expression of
microglia M2 markers either in young Tg2576 hippocampus
or in primary astrocyte-microglia cultures, suggesting
its potential therapeutic eﬃcacy as microglial modulator in
the early phase of AD.
This article is part of a Special Issue entitled: Inﬂammation
in Nervous System Disorders  2014 IBRO. Published by
Elsevier Ltd. All rights reserved.
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Alzheimer’s disease (AD) has a robust inﬂammatory
component owing to the microglial response to ﬁbrillar
forms of b-amyloid (Ab) that are deposited in the
diseased brain (Akiyama et al., 2000; Lucin and Wyss-
Coray, 2009). Microglia, the brain tissue macrophages,
are representatives of the innate immune system. Their
exposure to Ab stimulates canonical host-defense
mechanisms, resulting in the elaboration of an array of
immune mediators including reactive oxygen and
nitrogen species, chemokines and inﬂammatory cyto-
kines. Microglial-mediated inﬂammation has been argued
to be a critical contributor to AD pathogenesis. Microglia
number in the brain increases in proportion to the plaque
dimension, possibly to regulate plaque dynamics
through Ab clearance and phagocytosis. However, the
2 V. Porrini et al. / Neuroscience xxx (2014) xxx–xxxaccumulation of deposited forms of amyloid suggests that
in AD endogenous microglia are deﬁnitely insuﬃcient or
‘‘impaired’’ in suppressing plaque formation (Grathwohl
et al., 2009). The persistence of activated microglia and
their secretion of pro-inﬂammatory cytokines and immune
mediators contribute to the well-documented pro-
inﬂammatory milieu in the AD brain, which further acts
to functionally inactivate the phagocytic machinery
(Koenigsknecht-Talboo and Landreth, 2005).
The activation states of peripheral macrophage
classiﬁed as M1 (‘‘classically activated’’) or M2
(‘‘alternatively activated’’), have been recently proposed
also to describe the dual phenotype acquired by
activated microglia in the central nervous system
(Boche et al., 2013). M1 activation is associated with
the expression of pro-inﬂammatory molecule like Tumor
Necrosis Factor alpha (TNFa), Interleukin 1 beta (IL-1b),
inducible Nitric Oxide Synthase (iNOS), Interferon
gamma. The M2 activation state is related to the
production of anti-inﬂammatory cytokines and markers
of phagocytosis. It is characterized by expression of
genes like Mannose Receptor type C 1 (MRC1/CD206),
a cell surface receptor involved in antigen recognition
and presentation as well as in phagocytosis of
macrophages (Colton et al., 2006), and Arginase 1
(ARG1) involved in mechanism of protection and repair
of the extracellular matrix (Colton et al., 2006). Among
M2 genes associated with tissue remodeling, there are
Found in Inﬂammatory Zone (FIZZ1) and Chitinase 3-like
3 (Ym1), the mammalian lectin associated with recon-
struction of extracellular matrix by binding heparan sulfate
(Colton, 2009). Lastly, Triggering Receptor Expressed on
Myeloid cells 2 (TREM2) is a member of the innate
immune receptor TREM family which enhances phagocy-
tosis by microglia (Piccio et al., 2007). TREM2 could be
relevant to the removal of cell debris as well as the clear-
ance of amyloid proteins in AD, (Piccio et al., 2007;
Takahashi et al., 2007; Frank et al., 2008) and suppres-
sion of inﬂammatory response, including cytokine produc-
tion and secretion. The phagocytic proﬁle of microglia is
also crucial in the ‘‘resting’’ condition, during which they
continuously survey the brain environment by extending
and retracting their processes. It has been demonstrated
that microglia can eliminate synaptic elements, neuronal
precursors, and redundant newborn cells during adult
neurogenesis (Sierra et al., 2010). Beside enabling syn-
aptic pruning (Paolicelli et al., 2011), microglia modulate
synaptic activity and plasticity (Moriguchi et al., 2003)
and are fundamental in experience-mediated remodeling
of neuronal circuits in diseased and healthy brain
(Nimmerjahn et al., 2005; Wake et al., 2009; Rogers
et al., 2011; Tremblay et al., 2010, 2012; Schafer et al.,
2012; Bechade et al., 2013; Sogn et al., 2013; Ji et al.,
2013; Zhan et al., 2014).
CHF5074 (CSP-1103), 1-(30,40-dichloro-2-ﬂuoro[1,10-bip-
henyl]-4-yl)cyclopropanecarboxylic acid, has been recently
shown to bind and inhibit amyloid precursor protein
(APP) intracellular domain (AICD) (Branca et al., 2014).
CHF5074 actively lowers plaque burden in the
hippocampus and cortex of AD mice (Imbimbo et al.,
2007a, 2009). It reduces cognitive deﬁcits and microglialPlease cite this article in press as: Porrini V et al. CHF5074 (CSP-1103) induces
glial cultures exposed to beta-amyloid. Neuroscience (2014), http://dx.doi.org/1activation in adult TASD-41 (Imbimbo et al., 2009) and
aged Tg2576 transgenic mice (Sivilia et al., 2013) when
administered at 6 months of age (375 ppm in the diet),
respectively for 6 and 13 months. The beneﬁcial eﬀects
of CHF5074 on memory in aged AD mice were found to
be associated with partial resolution of microglia
immunoreactivity around the plaques. Additional studies
demonstrated that even administered in a subchronic
way (4-week), CHF5074 can fully reverse recognition
memory impairment in young, plaque-free Tg2576 mice.
In 5-month-old Tg2576 mice CHF5074 treatment rescued
long-term potentiation in the hippocampus and decreased
hyperphosphorylated tau without aﬀecting soluble or olig-
omeric brain Ab levels (Balducci et al., 2011). Eight-day
treatment with CHF5074 also restored cortical acetylcho-
line release (Giuliani et al., 2013) and regulated extracel-
lular glutamate levels (Beggiato et al., 2014) in pre-plaque
Tg2576 mice. So far no information exists about the
microglia activation state in young Tg2576, as well as
the impact of CHF5074 treatment on early presumed
microglia changes. Though clinical studies in healthy
subjects (Imbimbo et al., 2013) and in patients with mild
cognitive impairment (MCI) (Ross et al., 2013) showed
that CHF5074 can dose-dependently reduce CSF levels
of TNFa and sCD40L. As CHF5074 did not cause any
concomitant change in the CSF level of Ab, the reduction
of neuroinﬂammatory biomarkers in humans appears to
occur independently from any eﬀect on c-secretase
activity.
The aim of the present study was to evaluate the
microglial expression proﬁle in young, plaque-free
Tg2576 mice and the modulatory activity of CHF5074
treatment either in mice or in primary mixed astrocyte-
microglia cultures exposed to b-amyloid1–42 (Ab42).
EXPERIMENTAL PROCEDURES
Primary cell culture
C57BL/6 mice were purchased from Charles River,
Wilmington, MA, USA. Mixed glial cell cultures were
prepared from the brains of 1–3-day newborn mice.
Brieﬂy, after carefully removing meninges and large
blood vessels, the brains were pooled and then
dissociated by manual dispersion with a ﬁre-polished
Pasteur pipette. The cells were allowed to attach and
grow at 37 C in DMEM supplemented with 10% fetal
bovine serum (FBS) (Euroclone, Milan, Italy), 4 mM
L-glutamine, 200U/ml penicillin/streptomycin in a water
saturated atmosphere containing 5% CO2 for 14 days. A
near 10% of microglia was present in the mixed
microglia-astrocyte cultures.
Beta-amyloid toxicity
Soluble Ab42 (Life Technologies, Monza, Italy) were
dissolved in sterile water to a ﬁnal concentration of
2.5 mM, divided into aliquots and frozen.
For experiments, mixed glial cells were incubated with
soluble (not aggregated) Ab42, added at a concentration
of 10 lM, in the presence of CHF5074 3 lM (Chiesi
Farmaceutici, Parma, Italy), Ibuprofen 3 lM and 500 lMmicroglia alternative activation in plaque-free Tg2576 mice and primary
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3 lM and 500 lM (Chiesi Farmaceutici) (solved in 0.2%
dimethyl sulfoxide) or vehicle. Incubations were carried
out for diﬀerent times (from 1 to 8 days) in DMEM
medium. At the end of these periods, total RNA was
isolated and retro-transcripted to cDNA for real-time
quantitative retro transcription-polymerase chain
reaction (qRT-PCR) analysis.Animals and treatments
The Tg2576 transgenic mouse carries a transgene coding
for the 695-amino acid isoform of human APP derived
from a large Swedish family with early-onset AD (Hsiao
et al., 1996). Five-month-old female Tg2576 mice and
age-matched wild-type littermates were used. Mice
(n = 10 per Tg2576 treatment group, n= 10 per wild-
type) were treated for 4 weeks with CHF5074 (375 ppm
in the diet, corresponding to approximately 60 mg/kg/
day) or with standard diet. Animal care and treatments
were in accordance with European Community Council
directives (86/609/EEC) and in conformity with protocols
approved by ethics committee for animal experimentation
of University of Bologna (n. 72, October 01, 2012). At the
end of treatment, mice were sacriﬁced by cervical disloca-
tion. Their brains were removed, the hippocampus and
cerebral cortex were dissected and immediately frozen
to be subsequently processed for RNA extraction.Real-time quantitative reverse transcription-
polymerase chain reaction (qRT-PCR)
Total RNA was puriﬁed from cells and tissues using the
RNeasy Mini Kit for total RNA extractions (Qiagen,
Valencia, CA, USA). RNA was reverse transcribed using
the Quantitect Reverse Transcription Kit (Qiagen) with
optimized mix of oligo-dT and random primers as primer
and 1 lg of total RNA from mixed glial cultures and
cortical and hippocampal tissues. The reverse
transcription reaction comprised 2 main steps:
elimination of genomic DNA and reverse transcription.
In the ﬁrst step, 1 lg of total RNA was added to 7
gDNA Wipeout Buﬀer resuspended in RNAse–DNase
free water (ﬁnal volume of 14 ll) and brieﬂy incubated
at 42 C for 2 min to eﬀectively remove contaminating
genomic DNA. After genomic DNA elimination, a mix of
5 Quantiscript RT Buﬀer, that included dNTPs and
Mg2+, Quantiscript Reverse Transcriptase, that also
contained RNase inhibitor, and RT Primer Mix was
added to the RNA sample to reach a ﬁnal volume of
20 ll. The entire reaction was incubated at 42 C for
15 min and was then inactivated at 95 C for 3 min.
Retrotranscribed cDNA was ampliﬁed in 25 ll SYBR
Green real-time PCR reactions containing 2–8 ll of
cDNA, 12.5 ll of 2 iQ SYBR Green Supermix (Bio-
Rad, Hercules, CA, USA), and 1 ll of each 10 lM
optimized forward and reverse primers in 8.5–2.5 ll
RNase-free water. PCR reaction was performed using a
3-stage program: 3 min at 50 C, 10 min at 95 C and 40
cycles of 30 s at 94 C and 45 s at 60 C. Incorporation
of the SYBR Green dye into the PCR products was
monitored in real-time with a BIORAD iCycler detectionPlease cite this article in press as: Porrini V et al. CHF5074 (CSP-1103) induces
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cycle (CT) at which the exponential ampliﬁcation of PCR
products began. Each reaction was performed in
triplicate. For standardization of quantiﬁcation, b-actin
was ampliﬁed simultaneously.
Western blot analyses
Brain lysates from hippocampi of WT and Tg mice and
immunoblot analyses were carried out as previously
described (Lanzillotta et al., 2011).
Total extracts (50 lg proteins/sample) were
suspended in the sample-loading buﬀer and resolved by
4–12% SDS/polyacrylamide gel. Immunodetection was
performed by incubating the membrane overnight at
4 C, with the following primary antibodies: anti-
bIII-tubulin rabbit antibody (1:2000; Sigma–Aldrich);
anti-phospho-GSK-3b(Ser9) rabbit antibody (1:1000;
Cell Signaling, Danvers, MA, USA), which identify the
inactivated kinase; anti-GSK-3b rabbit antibody (1:1000;
Cell Signaling). Quantiﬁcation of protein expression was
performed by densitometry analysis of immunoblots,
using GelPro analysis software. Each protein band was
normalized to the relative bIII-tubulin signal.
Statistical analysis
Data were analyzed with Student’s t-test for independent
data or with a 2-way ANOVA (with genotype and
treatment as ﬁxed factors), followed by the Holm-Sidak
test for multiple comparison. Data are presented as
mean ± SEM. P< 0.05 was considered as signiﬁcant.
RESULTS
Subchronic treatment with CHF5074 reduces
microglia anti-inﬂammatory/phagocytic transcription
in the hippocampus of 5-month-old Tg2576 mice
As previously described (Balducci et al., 2011), 5-month-
old female Tg2576 mice were treated with CHF5074-
medicated diet or normal diet for 4 weeks. After treatment,
mice were sacriﬁced and the hippocampus and cerebral
cortex tissues processed for real-time qRT-PCR analysis
of mRNA expression.
To investigate classical pro-inﬂammatory transcripts
we analyzed TNFa, IL-1b and iNOS mRNAs. As
markers of ‘‘alternative’’ microglial activation we
investigated TREM2, MRC1/CD206, and Ym1. TNFa
was nearly undetectable in all experimental groups (data
not shown) and no diﬀerence in the expression levels of
IL-1b and iNOS was found among wild-type and Tg2576
mice treated with either vehicle or CHF5074 (Fig. 1A).
Conversely, when compared to wild-type littermates,
Tg2576 mice displayed a signiﬁcant lower expression of
TREM2 and MRC1/CD206 together with a trend to a
lower expression for Ym1 in the hippocampus (Fig. 1B).
Treatment with CHF5074 signiﬁcantly increased two of
the three M2 markers. It restored the expression of
MRC1/CD206 and induced the expression of Ym1, while
it did not modify the level of TREM2 mRNA. The
changes in M2 anti-inﬂammatory/phagocytic markers
appeared to be hippocampus-speciﬁc as the cerebralmicroglia alternative activation in plaque-free Tg2576 mice and primary
0.1016/j.neuroscience.2014.10.029
Fig. 1. Eﬀect of CHF5074 on pro-inﬂammatory and anti-inﬂammatory/phagocytic transcripts in the hippocampus and cerebral cortex of 5-month-old
Tg2576 mice. (A) Evaluation of IL-1b and iNOS mRNAs by qRT-PCR in the hippocampus. Expression of IL-1b and iNOS was similar in Tg2576 mice
and wild-type mice. No change was produced by CHF5074 subchronic treatment in Tg2576 mice. (B) Measurement of TREM2, MRC1/CD206 and
Ym1 mRNA levels by qRT-PCR in the hippocampus. Lower expression of TREM2 and MRC1/CD206 was detected in Tg2576 mice when compared
to wild-type mice. Ym1 showed a trend to decrease in Tg2576. Subchronic treatment with CHF5074 increased the expression of MRC1/CD206 and
Ym1, whereas it did not change the expression of TREM2. (C) Evaluation of IL-1b and iNOS expression by qRT-PCR in cerebral cortex. iNOS
mRNA was reduced and IL-1b was not modiﬁed in Tg2576 mice compared to wild-type mice. No signiﬁcant eﬀect was produced by CHF5074
treatment. (D) Analysis of TREM2, MRC1/CD206 and Ym1 mRNA levels in cerebral cortex. A signiﬁcant decrease of TREM2 mRNA but no change
in MRC1/CD206 and Ym1 expression was detected in Tg2576 mice. CHF5074 treatment did not aﬀect the expression of the M2 markers
(⁄p< 0.05, ⁄⁄p< 0.01, ⁄⁄⁄p< 0.001; two-way ANOVA followed by Holm-Sidak test for comparison vs Tg2576 Vehicle group).
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(Fig. 1D) and iNOS (Fig. 1C). Both modiﬁcations were
unresponsive to CHF5074 treatment.
Analogous experimental treatment in plaque-free
Tg2576, showed the capability of CHF5074 to reduce
both cerebral hyper-phosphorylated and total tau
(Balducci et al., 2011), an important target of glycogen
synthase kinase-3 beta (GSK-3b) in AD (Lanzillotta
et al., 2011). As a neurochemical parameter of
CHF5074 eﬀect in the brain, we measured the hippocam-
pal levels of total GSK-3b and the inactive GSK-3b phos-
phorylated (pSer9) form. In line with previous evidence
obtained in TASD-41 AD mice (Lanzillotta et al., 2011),
CHF5074 treatment decreased the GSK-3b total amount
without aﬀecting the p-GSK-3b/GSK-3b ratio (data not
shown).Ab42 induces expression of pro-inﬂammatory
cytokines and reduces microglia anti-inﬂammatory/
phagocytic transcription in astrocyte-microglia
cultures
To investigate the activity of CHF5074 in modulating
microglial activation independently from interaction
with neuronal or circulating factors we adopted thePlease cite this article in press as: Porrini V et al. CHF5074 (CSP-1103) induces
glial cultures exposed to beta-amyloid. Neuroscience (2014), http://dx.doi.org/1cell-based model of mixed astrocyte-microglia cultures
exposed to Ab42.
Astrocyte-microglia cultures were exposed to 10 lM
concentration of soluble Ab42 and the RNA was isolated
at diﬀerent time-points, i.e. 1, 2, 3 and 8 days after Ab42
addition (Fig. 2). By qRT-PCR we analysed the
expression of IL-1b and TNFa, as markers of M1
microglial activation, and MRC1/CD206 as a marker of
phagocytic M2 microglia activation (Town et al., 2005;
Mosser and Edwards, 2008; Martinez et al., 2009). No
expression change was detected at day 1, but a major
pro-inﬂammatory activation of microglia was measured
2 days after Ab42 addition. The expression of IL-1b
(Fig. 2A) and TNFa (Fig. 2B) markedly increased, while
expression of MRC1/CD206 decreased (Fig. 2C). These
changes were less evident 3 days after the Ab42 addition
and totally disappeared after 8 days of treatment.CHF5074 reduces pro-inﬂammatory transcription and
increases microglia anti-inﬂammatory/phagocytic
transcription in astrocyte-microglia cultures exposed
to Ab42
We examined the eﬀect of CHF5074 on the inﬂam-
matory response induced by Ab42. Mixed cultures ofmicroglia alternative activation in plaque-free Tg2576 mice and primary
0.1016/j.neuroscience.2014.10.029
Fig. 2. Evaluation of Ab42 treatment on M1 and M2 markers levels in
astrocyte-microglia cultures. Astrocyte-microglia cultures’ exposure
to Ab1-42 (Ab42) for 1, 2, 3 or 8 days induced the expression of pro-
inﬂammatory cytokines IL-1b (A) and TNFa (B), but depressed the
expression of MRC1/CD206 (C), as measured by qRT-PCR.
Changes in expression levels were maximal after 2 days of Ab42
exposure and fall down at 8 days. (⁄p< 0.05; Student’s t-test for
independent data for comparison vs corresponding vehicle).
V. Porrini et al. / Neuroscience xxx (2014) xxx–xxx 5astrocyte-microglia were exposed to Ab42 with or without
CHF5074 at 3 lM, a concentration reproducing the brain
levels of CHF5074 measured after administration of
CHF5074-medicated diet (375 ppm) in TASD-41 micePlease cite this article in press as: Porrini V et al. CHF5074 (CSP-1103) induces
glial cultures exposed to beta-amyloid. Neuroscience (2014), http://dx.doi.org/1(Imbimbo et al., 2009). Cultures were examined for
cytokine expression after 2 or 8 days (Fig. 3). The expression
of iNOS, as well as TNFa and IL-1b, increased after
2-day-treatment with Ab42, conﬁrming the ability of Ab42
to induce the pro-inﬂammatory response in mixed glial
cultures. Co-exposure to CHF5074 decreased IL-1b as
well as TNFa, and iNOS mRNA expression (Fig. 3A).
We also investigated alternative microglial activation
markers in mixed glial cultures exposed to Ab42 with
and without CHF5074 for 2 days or 8 days (Fig 3B, D).
We checked the mRNA expression of MRC1/CD206
with TREM2 and, being undetectable the expression of
Ym1 in cultured cells (data not shown), we included
ARG1. Two-day exposure to Ab42 signiﬁcant reduced
the MRC1/CD206 expression by about 50% of basal
value (Fig. 3B). This eﬀect was reversed by CHF5074
which produced a near threefold increase of MRC1/
CD206 mRNA level. Ab42 treatment did not aﬀect
TREM2 expression per se, but CHF5074 signiﬁcantly
increased TREM2 mRNA by near 60% over the basal
level. No change of ARG1 expression was detected in
primary cultures at any condition tested (Fig. 3B). After
8 days of Ab42 treatment, M1 and M2 mRNAs returned
to the basal values and CHF5074 addition was unable
to induce any further change (Fig. 3C, D).
Chemically, CHF5074 is a nonsteroidal anti-
inﬂammatory drugs (NSAID) derivative but it is devoid of
inhibitory activity on cyclooxygenase up to 300 lM
concentrations (Imbimbo et al., 2007b). We then investi-
gate whether CHF5074 modulatory eﬀects on microglia
transcription were reproduced by NSAIDs, the cyclooxy-
genase inhibitor ibuprofen, or the NSAID derivative R-ﬂur-
biprofen devoid of cyclooxygenase inhibitory activity.
Astrocyte-microglia cultures were exposed for 2 days to
Ab42 with or without ibuprofen at 3 lM and 500 lM, or
with R-ﬂurbiprofen at 3 lM and 100 lM (Fig. 4). In line
with previous evidence showing anti-inﬂammatory activity
of the NSAID (Stratman et al., 1997), either ibuprofen of
R-ﬂurbiprofen signiﬁcantly reduced the iNOS expression
during Ab42 exposure (Fig. 4A). Conversely neither
ibuprofen nor R-ﬂurbiprofen increased the expression of
anti-inﬂammatory/phagocytic markers TREM2 and
MRC1/CD206 (Fig. 4B, C).DISCUSSION
This study shows that CHF5074 can act as a microglia
modulator, able to polarize microglia from the ‘‘pro-
inﬂammatory M1’’ to the ‘‘alternative M2’’ phenotype.
In mouse mixed glial cultures, Ab42 exposure induced
the pro-inﬂammatory expression of TNFa, IL-1b and
iNOS and reduced the expression of MRC1/CD206, a
marker of the anti-inﬂammatory/phagocytic activation
state of microglia. The eﬀect peaked at two days and
fell to basal level at 8 days. CHF5074 co-exposure
limited the pro-inﬂammatory M1 gene expression and
increased mRNA levels of M2 microglia markers MRC1/
CD206 and TREM2. These data, obtained in a cell-
based model of Ab-induced neuroinﬂammation, indicate
that CHF5074 can directly modulate the phenotype of
active microglia, independently of the interaction withmicroglia alternative activation in plaque-free Tg2576 mice and primary
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Fig. 3. Eﬀects of CHF5074 on expression of pro-inﬂammatory and anti-inﬂammatory/phagocytic markers in astrocyte-microglia cultures exposed to
Ab42. (A) qRT-PCR analysis of TNFa, IL-1b and iNOS expression in astrocyte-microglia cultures exposed to 10 lM Ab42. Two days exposure of
cells to 3 lM CHF5074 decreased the Ab42-induced expression of pro-inﬂammatory cytokines TNFa, IL-1b and iNOS (B) qRT-PCR analysis of
MRC1/CD206, ARG1 and TREM2 expression in astrocyte-microglia cultures exposed to Ab42 for 2 days. Addition of 3 lM CHF5074 increased the
MRC1/CD206 and TREM2 expression reduced by Ab42. No change was observed in ARG1 expression level (C) TNFa, IL-1b and iNOS expression
in cells exposed to Ab42 with or without CHF5074 for 8 days. Neither Ab42 alone nor in combination with CHF5074 modify the microglia activation
state. (D) Quantiﬁcation of MRC1/CD206, ARG1 and TREM2 expression in cells exposed to Ab42 with or without CHF5074 for 8 days. No changes
in gene expression are observed in cultures exposed to Ab42 alone or and in the presence of CHF5074. (
⁄p< 0.05, ⁄⁄p< 0.01, ⁄⁄⁄p< 0.001;
Student’s t-test for independent data for comparison vs corresponding Ab42).
Fig. 4. Eﬀects of ibuprofen and R-ﬂurbiprofen on expression of pro-inﬂammatory and anti-inﬂammatory/phagocytic markers in astrocyte-microglia
cultures exposed to Ab42. Two days exposure of astrocyte-microglia cultures to ibuprofen (3 lM or 500 lM) and R-Flurbiprofen (3 lM or 100 lM), in
the presence of 10 lM Ab42, reduced the expression of iNOS (A). Neither ibuprofen nor R-ﬂurbiprofen aﬀected the expression level of TREM2
(B) and MRC1/CD206 (C) (⁄p< 0.05; Student’s t-test for independent data for comparison vs corresponding Ab42).
6 V. Porrini et al. / Neuroscience xxx (2014) xxx–xxxneuronal or circulating cells and apart from modulation of
Ab generation. The results are also in line with previous
clinical evidence showing that CHF5074 administration
reduces TNFa levels in cerebrospinal ﬂuid of healthy
subjects (Imbimbo et al., 2013) and of MCI patients
(Ross et al., 2013). Worth of note, the peculiar modulation
of M2 microglial transcription by CHF5074 in primaryPlease cite this article in press as: Porrini V et al. CHF5074 (CSP-1103) induces
glial cultures exposed to beta-amyloid. Neuroscience (2014), http://dx.doi.org/1cultures was not reproduced by the classical NSAID
ibuprofen or by the atypical NSAID R-ﬂurbiprofen devoid
of cyclooxygenase inhibitory activity (Morihara et al.,
2002). In line with previous evidence (Ogawa et al.,
2000; Hinz et al., 2000; Heneka et al., 2005), either
ibuprofen or R-ﬂurbiprofen diminished iNOS mRNA, but
neither compound modiﬁed MRC1 or TREM2 expression.microglia alternative activation in plaque-free Tg2576 mice and primary
0.1016/j.neuroscience.2014.10.029
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of-function mutations in TREM2 gene are associated with
a signiﬁcant increase in the risk of AD (Guerreiro et al.,
2013). This evidence has enormously emphasized the
role of microglia alternative activation in the pathogenesis
of AD. It was suggested that drugs modulating inﬂamma-
tion by switching the activation state of microglia toward
the M2 state, rather than totally repressing microglia reac-
tivity, might make a good therapeutic.
We thus investigated the capability of CHF5074 to
modulate microglial transcription in AD mice. Previous
studies in Tg2576 mice showed that the inﬂammatory
M1 expression is present only at later stages of
disease, from 13 months onward (Kotilinek et al., 2008),
and that at 18 months of age both M1 and M2 markers
are expressed (Colton et al., 2006). Though, no evidence
exists about the expression level of M2 markers at the ear-
liest stage of disease (6 months of age) when, in the
absence of amyloid plaque accumulation, Tg2576 mice
already display cognitive deﬁcits and impairment of
hippocampal synaptic plasticity (Jacobsen et al., 2006;
Balducci et al., 2011). We originally demonstrated that
the expression of microglia anti-inﬂammatory/phagocytic
markers TREM2, MRC1/CD206 and Ym1 is signiﬁcantly
reduced in the brain of 6-month-old Tg2576 mice, while
the expression of pro-inﬂammatory IL-1b and iNOS is
unchanged. Treatment with CHF5074 eﬃciently reverses
the depression of two of the three M2 markers, MRC1/
CD206 and Ym1. A body of evidence proves the pivotal
role of microglial phagocytosis in structural remodeling
of neuronal circuits and in modulation of synaptic activities
and plasticity (Sierra et al., 2010; Tremblay et al., 2010;
Schafer et al., 2012; Tremblay et al., 2012). We here
report that cognitive defects in young Tg2576 mice, i.e.,
reduced contextual and recognition memory and
decreased synaptic plasticity in the hippocampus
(Jacobsen et al., 2006; Balducci et al., 2011), are tempo-
rally associated with ‘‘reduced or impaired’’ transcription
in anti-inﬂammatory/phagocytic microglia. Pharmacologi-
cal intervention through subchronic administration of
CHF5074, limiting memory deﬁcits and synaptic dysfunc-
tion in young Tg2576 mice (Balducci et al., 2011),
switches on the transcriptional activity of phagocytic
microglia.
Worth of note, this switch was found in the
hippocampus, the brain structure primarily involved in
spatial and recognition memory and one of the ﬁrst
regions aﬀected in AD. Changes in microglial
transcription were less evident in cerebral cortex of
young Tg2576 mice and consequently the eﬀect of
CHF5074 was much weaker there.
The mechanism by which CHF5074 can induce
microglia ‘‘alternative’’ transcription remains to be
explored yet. Both CHF5074 and ibuprofen have been
shown to lower the GSK-3b level (Lanzillotta et al.,
2011), an eﬀect that could contribute to their common
activity in reducing the expression of proinﬂammatory
cytokines and iNOS (Martin et al., 2005; Green and
Nolan, 2012) in primary astrocyte-microglia exposed to
Ab42. Though, alternative pathways diﬀerentiating
CHF5074 from ibuprofen or R-ﬂurbiprofen in switchingPlease cite this article in press as: Porrini V et al. CHF5074 (CSP-1103) induces
glial cultures exposed to beta-amyloid. Neuroscience (2014), http://dx.doi.org/1microglia polarization, deserve to be investigated. Among
possible mechanisms, AICD-dependent eﬀects targeted
by CHF5074 (Branca et al., 2014), but still unexplored in
glial cells, should be taken into consideration.
While in the past neuroinﬂammation was considered
simply an epiphenomenon of AD, now it is rapidly being
recognized as a crucial step in the AD pathogenesis.
This hypothesis has been bolstered by recent genome-
wide association studies that have uncovered microglial
TREM2, Complement Receptor 1, and Cluster of
diﬀerentiation 33 as key AD risk genetic factors (Zhang
et al., 2013). The old approach of achieving broad sup-
pression of inﬂammation with NSAIDs has not produced
positive results for either treatment (Imbimbo et al.,
2010) or prevention of AD (The Alzheimer’s Disease
Anti-inﬂammatory Prevention Trial Research Group,
2013). One possible explanation for this is that modulating
neuroinﬂammation, rather than suppressing it, may ulti-
mately prove to be the most beneﬁcial strategy against
AD. CHF5074 might represent an innovative approach
for balancing neuroinﬂammation in the AD brain.
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